Saturday, June 23, 2018

It just keeps getting better

On June 11 we traveled to Harborview in Seattle for my annual cognitive testing—almost four hours worth. I was anxious because I had slept very poorly the night before, and I had foolishly scheduled the testing for the afternoon. I’m a morning person, and when I’ve missed sleep it might not hit me until the afternoon. But, we went ahead with the tests, and I was surprised at how well I felt about how I’d done.

Not being a patient person, I wanted to know the results immediately. But they needed to be analyzed and assessed before the doctors could share them with me. So I needed to wait; we would need to return more than a week later to hear the results.

Before the test began, I had a discussion with the new neuropsychologist who will be following my case. We discussed the status of the SNIFF (insulin) study, and the fact that I had been getting quarterly psychometric testing from them. I wondered about how “the practice effect” might influence my results. She said that was a consideration, and she had made some changes to the test suite to differentiate these tests from what I had taken before.

Yesterday (June 23) we made the trip back over the mountains to meet with my neurologist and review the results. They were even better than I had anticipated.

It was true that the neuropsychologist had shaken up the test suite, and so I can’t make the sort of year-over-year, test-by-test comparisons that I’ve made before. Nevertheless, there were 42 individual assessments, and I could easily get an overall sense for how things were compared to 2015 through 2017. In 23 tests I scored high average, superior, or very superior. As I write this, I’m still in Seattle, and I don’t have my old tests available. But I don’t recall ever having received a “very superior” before. There was only one low average, and none of the below average scores that I had sometimes scored in the past.

In her summary assessment, the neuropsychologist identified five areas in which I had improved (single-trial learning and delayed recall from a word list, both semantic and phonemic verbal fluency, basic attention, and visual tracking/psychomotor speed), adding that some of them may have been inflated due to the practice effect. But from a broad cognitive standpoint, she wrote, “Mr. Brown is doing very well across all domains.”

My neurologist was quite enthusiastic about the results, and agreed that the improvements were likely a consequence of the lifestyle changes I’ve made. She mentioned that at least one other professional in her office had gotten a copy of Beating the Dementia Monster.

During the visit, we reviewed images from my most recent MRI (February) and compared it to the MRIs of 2012, 2015, and 2017. Some of these were done using the research machine for the SNIFF study. What we specifically looked for was a way of understanding the assessments of hippocampus volume. (The 2015 radiologist report had me in the 36 percentile of people my age, but the SNIFF study reports had me at less than the 1 percentile.) She didn’t try to assign numeric values from the images, but it was evident that there was little or no deterioration from the time I made the lifestyle changes I describe in Beating the Dementia Monster (December 2015). Nevertheless, there were notable changes (atrophy) between the 2012 images and the 2018 images.

So how do these results affect my future course? The neurologist said that we should not do cognitive testing next year. I will have a closeout suite for the SNIFF study in August, but I should take a break from cognitive testing after that until the summer of 2020. She said I should return next summer for an annual visit to see how things are going. We’ll be alert for anything unusual or unexpected, especially when the SNIFF study ends, and I’m taken off the insulin.

I won’t lie. Some mornings it’s really hard to get on that treadmill and keep it going for 45 minutes. But it’s really worth it.


No comments:

Post a Comment

Welcome Kisunla

We reported previously that the FDA's advisory panel had recommended approval of the monoclonal antibody treatment donanemab.  This foll...